OBJECTIVE: To investigate the analgesic effect of locally injecting a "cocktail" analgesia containing a high-dose compound betamethasone during revision hip arthroplasty, and also to study the usage of opioid drugs. METHODS: A retrospective analysis was conducted on the clinical data of 180 patients who underwent revision hip arthroplasty due to aseptic loosening of the hip prosthesis between January 2015 and December 2021. Among them, 95 patients received intraoperative injection of "cocktail" analgesia containing high-dose compound betamethasone (group A), and 85 patients received intraoperative injection of traditional "cocktail" analgesia (group B). There was no significant difference in baseline data such as gender, age, body mass index, presence or absence of diabetes mellitus between the two groups ( P>0.05). The hospital stay, use of opioid drugs within 72 hours, and the incidence of adverse reactions within 72 hours after operation [including nausea and vomiting, insomnia, deep venous thrombosis (DVT), infection, etc.] were recorded and compared between the two groups. The pain relief of patients was evaluated using the static and dynamic visual analogue scale (VAS) scores at 12, 24, 48, and 72 hours after operation. The incidence of complications (including prosthesis re-loosening, hip joint dislocation, hip joint stiffness, limping, chronic pain, etc.) at 2 years after operation was recorded, and the Harris Hip Score (HHS) was used to evaluate the function at 2 years after operation. RESULTS: In group A, the utilization rate of opioid drugs within 72 hours after operation was significantly lower than that in group B ( P<0.05). However, there was no significant difference between the two groups in terms of hospital stay, as well as the incidence of adverse reactions such as nausea and vomiting, insomnia, DVT, and infection within 72 hours after operation ( P>0.05). The VAS scores of both groups decreased with time, and the differences between different time points were significant ( P<0.05). The static and dynamic VAS scores of group A were significantly lower than those of group B at 12, 24, and 48 hours after operation ( P<0.05), but there was no significant difference in static and dynamic VAS scores between the two groups at 72 hours after operation ( P>0.05). All patients in both groups were followed up 2-8 years, with an average of 5.73 years. At 2 years after operation, no significant difference was found between the two groups in the incidence of complications and HHS score ( P>0.05). CONCLUSION "Cocktail" analgesia containing a high-dose compound betamethasone for early analgesia after revision hip arthroplasty can effectively reduce postoperative pain and the use of opioid drugs, but will not increase the incidence of infection and DVT after operation.
Humans ; Arthroplasty, Replacement, Hip/adverse effects* ; Betamethasone/therapeutic use* ; Retrospective Studies ; Male ; Female ; Analgesics, Opioid/administration & dosage* ; Pain, Postoperative/prevention & control* ; Middle Aged ; Reoperation ; Aged ; Analgesia/methods* ; Adult ; Pain Measurement ; Pain Management/methods* ; Prosthesis Failure ; Hip Prosthesis

Administration, Cutaneous ; Administration, Topical ; Betamethasone Valerate ; therapeutic use ; China ; Clobetasol ; therapeutic use ; Cohort Studies ; Diabetes Mellitus ; epidemiology ; Ethnic Groups ; statistics & numerical data ; Female ; Glucocorticoids ; therapeutic use ; Humans ; Hyperlipidemias ; epidemiology ; India ; Lichen Planus ; drug therapy ; epidemiology ; Malaysia ; Male ; Middle Aged ; Multivariate Analysis ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Singapore ; epidemiology ; Triamcinolone ; therapeutic use

OBJECTIVETo investigate the effect of photodynamic therapy combined with compound betamethasone in the treatment of hypertrophic scar.

METHODS37 cases of keloid were divided into two groups, 19 cases in the treatment group, 18 cases in the control group. The patients in treatment group were treated with photodynamic therapy combined with compound betamethasone injection therapy. The patients in the control group were treated by compound betamethasone injection. The effect and recurrence rate were compared before and after treatment.

RESULTSThe effective rate was 89.5% in the treatment group, 55. 6% in the control group, showing significant difference between the two groups (P = 0.029) The relapse rate in treatment group was significantly lower than that in the control group (P = 0.047) CONCLUSIONS: Photodynamic therapy combined with compound betamethasone has good effect and safety for the treatment of hypertrophic scar. The combined treatment can reduce the treatment period and side effects

Betamethasone ; therapeutic use ; Case-Control Studies ; Cicatrix, Hypertrophic ; drug therapy ; Combined Modality Therapy ; methods ; Glucocorticoids ; therapeutic use ; Humans ; Photochemotherapy ; methods ; Recurrence

OBJECTIVETo investigate the treatment of auricular keloid with dinuclear surgery and intralesional injection of compound Betamethasone.

METHODSFrom Jan. 2008 to Jan. 2012, a total of 186 cases of ear keloid were treated by surgery only (22 cases), or intralesional injection of compound Betamethasone (34 cases), or combined dinuclear surgery with compound Betamethasone (130 cases). All the patients were followed up for one year. SPSS 16.0 software was used for statistical processing and analysis, and GraphPad inspection method for inspection.

RESULTSThe effective rate was 54.55% (12/ 22) in surgery group and 55.88% (19/34)in injection group. The recurrence was obvious in injection group during the follow-up period. The effective rate was as high as 96.92% (126/130) in combined group with recurrence in 4 cases, which was significantly higher than that in other 2 groups (P < 0. 01).

CONCLUSIONCombined dinuclear surgery and compound Betamethasone injection has a good therapeutic effect on auricular keloids.

Adolescent ; Adult ; Betamethasone ; therapeutic use ; Combined Modality Therapy ; Ear Auricle ; pathology ; Female ; Humans ; Injections, Intralesional ; Keloid ; surgery ; therapy ; Male ; Treatment Outcome ; Young Adult

Cutaneous pseudolymphoma is an uncommon, benign lymphoproliferative disorder of the skin. Although this condition is most commonly idiopathic, its occurrence has been associated with cosmetic tattoos. We report a unique case of cutaneous pseudolymphoma that occured after accidental, traumatic inoculation of a red pigment in a healthy 33-year-old woman.
Adult ; Betamethasone ; analogs & derivatives ; therapeutic use ; Biopsy ; Coloring Agents ; adverse effects ; Female ; Forehead ; pathology ; Humans ; Lacerations ; Lymphoproliferative Disorders ; diagnosis ; etiology ; Pseudolymphoma ; chemically induced ; diagnosis ; Skin ; pathology ; Skin Diseases ; chemically induced ; diagnosis ; Triamcinolone Acetonide ; therapeutic use

OBJECTIVE: To observe therapy efficacy of external auditory canal eczema by deeply injecting compound betamethasone and benzathine penicillin into patients muscles. METHOD: Sixty patients were randomly divided into two groups. In the treatment group 30 patients were deeply injected compound betamethasone injection 1 ml and benzathine penicillin 1 200 000 U into muscles on their hips both sides one times. In the control group 30 patients were given desloratadine 5 mg orally one times a day and amoxicillin capsules 0.5 mg orally three times a day, both kinds of medicine were continuously taken for one week. No other medication was used during the treatment of two groups, keeping skin clean and dry, and judge therapy efficacy after one week. RESULT: The cure rate was 60.00% and the total efficiency was 96.67% in the treatment group; the cure rate was 26.67% and the total efficiency was 73.33% in the control group. Compare with cure rate of two groups, chi2 = 6.67, P < 0.01, in which there was significant difference. Compare with total efficiency of two groups, chi2 = 4.71, P < 0.05, in which there was also significant difference. The therapy effect started in two hours quickly and in three days slowly in the treatment group, an average of 0.5 days. The therapy effect started in two days quickly and in five days slowly in the control group, an average of 2.5 days. CONCLUSION The method of the treatment group is simple, quick, effective and without adverse reaction.
Adolescent ; Adult ; Betamethasone ; therapeutic use ; Drug Therapy, Combination ; Ear Canal ; pathology ; Eczema ; drug therapy ; Female ; Humans ; Injections, Intramuscular ; Male ; Middle Aged ; Penicillin G Benzathine ; therapeutic use ; Young Adult

Anti-Inflammatory Agents ; therapeutic use ; Betamethasone Valerate ; therapeutic use ; Child, Preschool ; Coloring Agents ; adverse effects ; toxicity ; Dermatitis, Allergic Contact ; diagnosis ; drug therapy ; etiology ; Fusidic Acid ; therapeutic use ; Histamine Antagonists ; therapeutic use ; Humans ; Male ; Parenting ; Phenylenediamines ; adverse effects ; toxicity ; Protein Synthesis Inhibitors ; therapeutic use ; Singapore ; Tattooing ; adverse effects ; Time Factors

OBJECTIVETo discuss the treatment of compound betamethasone injection in cases with the intractable low-frequency sensorineural hearing loss (LFSNHL).

METHODSCompound betamethasone injection 1 ml had been injected postaural only once to 23 cases with the unilateral LFSNHL, then observe the effect and follow-up at least 6 months. At the same time, the same therapy used to 4 cases with the binaural LFSNHL. The control group gave Merislon and Sibelium peroral for 2 weeks to 18 cases with the unilateral LFSNHL.

RESULTSIn unilateral LFSNHL group, twelve cases recovered, 7 cases had the hearing improved and 4 cases were ineffective in 23 cases. The efficiency was 82.6%. 2 cases (2 ears) showed hearing falling at low-frequency after 2-3 months. Others didn't recur after 6 months. 1 case showed low-grade skin atrophy at the local injection part. No other side-effects showed. In 4 binaural cases, 2 cases in effect and the others had no effect, and the former recurred after 1-2 months. In control group, 1 week after the end of therapy, 3 cases (3 ears) recovered, 1 case (1 ear) recovered 2 weeks later after the end of therapy, and the 4 cases didn't recur after 2 months. The other 14 cases were ineffective.

CONCLUSIONSCompound betamethasone injection postaural treated intractable LFSNHL effectively, but no obvious efficiency to cases with the binaural LFSNHL. May be these cases have some relationship with autoimmune inner ear disease (AIED).

Adolescent ; Adult ; Betamethasone ; administration & dosage ; therapeutic use ; Female ; Hearing Loss, Sensorineural ; drug therapy ; Humans ; Male ; Middle Aged ; Young Adult

OBJECTIVETo evaluate the curative effects of Betamethasone for treatment of voice hoarseness of chronic hypertrophic laryngitis.

METHODSFrom July, 2001 to December, 2002, 48 cases of the chronic hypertrophic laryngitis had been treated by injected of Betamethasone at vocal cords. Fundamental frequency (FO), jitter, shimmer, normalized noise energy (NNE) acoustics' parameters were tested and paired t test were calculated. The voice quality of 1 month and 6 months after treatment were synthetically graded, one-way ANOVA and the DANCAN test were conducted.

RESULTSEight cases were injected under surface anesthesia with indirect laryngoscopy at the clinic service. Thirty-eight cases were injected under general anesthesias with micro-laryngoscopes. After six months following up, the voice hoarseness was obviously improved, the congestion or oedema of vocal cord was lessened, and the voice quality was improved as well. The results of F0, jitter, shimmer, NNE acoustics' parameters after treatment 6 months showed: 8 of 48 cases (17.39%) had treatment effect, 22 out of 48 cases (47.83%) had obviously effect, 10 out of 48 cases (21.74%) had cured. The total effectiveness had reached 86.96% (40 of 48 cases). Six of 48 cases (13.04%) was failure.

CONCLUSIONVocal cord injection of Betamethasone for the hoarseness of chronic hypertrophic laryngitis is an effective treatment method.

Adult ; Betamethasone ; administration & dosage ; therapeutic use ; Chronic Disease ; Female ; Humans ; Injections, Intralesional ; Laryngitis ; therapy ; Male ; Treatment Outcome ; Vocal Cords ; Voice Quality

Melasma is an acquired symmetric hypermelanosis characterized by irregular lightto gray-brown macules and patches on sun-exposed areas. Many therapeutic agents are available but are unsatisfactory. Recently, it has been demonstrated that lincomycin (LM) and linoleic acid (LA) can inhibit melanogenesis in vitro. Our purpose was to investigate the clinical efficacy of topical application of LM and LA in combination with betamethasone valerate (BV) in melasma patients. Fortyseven Korean female adults with clinically diagnosed melasma were enrolled in a 6-week, double-blind, randomized clinical trial. Patients were treated with one application of the vehicle (group A), 2% LM mixed with 0.05% BV (group B), or 2% LM mixed with 0.05% BV and 2% LA (group C) on the face every night. Determination of efficacy was based on the Melasma Area and Severity Index (MASI) score and objective assessment (no effect, mild, moderate, or excellent) at intervals of 2 weeks until the end of the study at 6 weeks. After 6 weeks, in comparison with the pre-treatment MASI score, the average MASI score of group C decreased to 68.9%, compared with 98% in group A (p<0.05) and 85.4% in group B. There was no statistically significant difference between group A and group B. Seven patients (43.7%) in group C revealed more than moderate improvement in objective assessment, compared with none in group A and two patients (12.5%) in group B. There were no significant side effects. Topical application of linoleic acid is considered to be effective in the treatment of melasma patients.
Administration, Topical ; Adult ; Anti-Bacterial Agents/administration & dosage/*therapeutic use ; Anti-Inflammatory Agents/administration & dosage/*therapeutic use ; Betamethasone 17-Valerate/administration & dosage/*therapeutic use ; Double-Blind Method ; Drug Combinations ; Female ; Glucocorticoids ; Humans ; Korea ; Lincomycin/administration & dosage/*therapeutic use ; Linoleic Acid/administration & dosage/*therapeutic use ; Male ; Melanosis/*drug therapy/pathology ; Middle Aged ; Molecular Structure ; Ointments